http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
B 형 만성활동성간염 환자에서 합성 Interferon Alpha 2b ( INTRON A(R) ) 의 효능 및 안정성 - 제 1 보 -
이창돈(Chang Don Lee),강무일(Moo Il Kang),유혜신(Hye Sin Yu),권혁호(Hyuk Ho Kwon),김재유(Jae Yoo Kim),정진우(Jin Woo Jeong),김부성(Boo Sung Kim) 대한내과학회 1987 대한내과학회지 Vol.32 No.6
N/A To evaluate the efficacy and safety of recombinant interferon alpha-2b (INTRONA®), in eleven patients with chronic active hepatitis (CAH) type B, a course of 28-day Intron A® was given daily subcataneous injection at a dose of 1 milion unit (MU) on the first day, 3 MU on the second, 5 MU on the 3rd to 7th, 3 MU on the 8th to 28th each. In 10 patients with HBeAg positive CAH type B, DNA polymerase and transaminoferase activities were assessed and compared before, during and after INTRON A administration. The peripheral blood white blood cell (WBC), granulocyte and platelet counts were checked. The results were as follows: 1) during administration of INTRON A, DNA polymerase activities were decreased significantly within first week and sustained in spite of persistent HBe antigenemia in all patients (p<0.05). Serum alanine aminotransferase (ALT) and aspartate aminotransferase were decreased significantly from 2 and 3 weeks after therapy respectively (p<0.01). 2) After discontinuation of INTRON A, improved transaminase level lasted for 4 weeks but rebound phenomena of DNA polymerase activities were observed 7 cases (70%) within 2 weeks, 3) during follow up period, transient increase of serum ALT activities were observed 9 cases within 12 weeks. One case of seroconversion (Anti-HBe) and one case of transient loss of HBeAg were observed at 16 week during mean follow up period of 30.3 weeks (range 16-58 weeks). But transient increment of serum ALT activities were observed 9 cases (90%) within 16 weeks. 4) In all 11 patients, peripheral white blood cell, granulocyte, platelet counts were decreased significantly within first week but not decreased further during INTRON A administration and recovered within 2 weeks after discontinuation of INTRON A. 5) Myalgia and fever were noted in 10 cases (91%) and headache and high fever (>38'C) were noted in 5 cases (45%) within 4 days. Mild anorexia (36%), hair loss (27%), diarrhea (9%), nausea (9%) were noted after 2 weeks. It suggested that subcutaneous injection of 3 MU INTRON A was safe and effective in decrement of DNA polymerase and transaminase activities in patients with CAH type B transiently. Long term therapy will be nessessary for the eradication of HBe Antigenemia and clinical improvement.
이창돈(Chang Don Lee),서정민(Chong Min Seo),조현미(Hyun Mi Cho),한남익(Nam Ik Han),최상욱(Sang Wook Choi),정진우(Jin Wu Jeong),박두호(Doo Ho Park),김부성(Boo Sung Kim) 대한내과학회 1989 대한내과학회지 Vol.36 No.6
N/A Previously, we reported that subcutaneous daily injections of 3 MU recobinant interferon alpha-2b (INTRON A®) for 28 days (short-term therapy) was safe and effective in the decrement of serum hepatitis B viral (HBV) replication markers and transaminase levels transiently in patients with chronic active hepatitis (CAH) type B. Therefore, to evaluate the safety and efficacy of INTRON A® in patients with CAH type B on the loss of HBV replication markers according to the duration of administration, we followed up (9~24 months) and compared patient, who were divided into two random long-term and short-term therapy groups (previously they were transient on each group). Negative conversion of DNA polymerase activities and HBV DNA, and normalization of ALT levels were observed in similar proportions in each group, but these changes were found to be transient in the short-term compared to the long-term group proportionally. In comparison of the characteristics between responders (10 cases) and nonresponders (12 cases) to INTRON A® just before treatment, 5 out of 6 females responded, compared to a male response of 5 out of 6; the younger patients (31.9±5.9 years) responded significantly better than the older (39.9±12.1 years), (p<0.05); but changes in serum ALT and AST levels, DNA polymerase activities and peripheral blood mono-lymphocyte counts were not significantly reported in the short-term group. (12 cases) and long-term therapy group (3 MU, thrice weekly for 12 weeks, 7 patients; or 24 weeks, 3 patients). On entry into the trial, there was no significant difference between each group in respect ot several clinical, biochemical and HBV replication markers and histology. With respect to changes in HBV replication makers during or after INTRON A® treatment, HBsAg negative conversion cases were absent on each group. However, HBeAg negative conversion cases were observed in only 3 of 12 cases on the short-term group but in 7 of 10 cases in the long-term group (2 cases in HBeAg negative conversion defference). We did not observe serious complication during and after the INTRON A® treatment. We concluded that subcutaneous injection of 3 MU of INTRON A® was safe and effective in decreasing the level of HBV replication markers and tran-saminase activities in patients with CAH type B, but long-term therapy rather than short-term therapy was necessary for the eradication of HBe antigenemia and clinical improvment for an extended period of time.
이창돈(Chang Don Lee),최상욱(Sang Wook Choi),박영민(Young Min Park),임계순(Kae Soon Im),박두호(Doo Ho Park),김부성(Boo Sung Kim) 대한내과학회 1988 대한내과학회지 Vol.34 No.6
N/A It is now generally accepted that the hpatitis R virus (HBV) is not directly cytopathic and that liver cell necrosis is dependent upon the hosts cellular immune response. To examine the pssible contribution of cellular immune regulatory mechanism to pathogenesis and progression of type B hepatitis in Korea, we evaluated the patterns of natural killer cell mediated cytotoxicity (NKMC) of peripheral blood lymphocyte in normal control subjects (25cases), asymptomatic carrier (AC; 18cases), acute viral hepatitis (AVH; 7cases) chronic active hepatitis (CAH;26cases), liver cirrhosis (LC;15cases) and primary hepatocellular carcinoma (HCC; 9 Cases). NKMC were assessed using 57Cr releasing cytotoxic assay against K562 target cells. The results were as follows: 1) In normal controls, NKMC were 52.8±8.1% (effector cell to target cell ratio; E:T=25:1) and 69.8±7.2% (E:T=50:1), No significant differences between male and female were seen. 2) In asymptomatic carrier, NKMC were 48.6±11.4% (E:T=25:1) and 68.1±7.8 (E:T=50:1). There was no significant difference between subjects with positive and negative hepatitis Be antigen. 3) In AVH and CAH, NKMC were 46.9±7.8%, 49.7±7.4% (E:T=25:1) and 65.4+4.5%, 67.5±6.2% (E:T = 50:1) respectively. There were no significant differences compared to normal controls, asymptomatic carrier, AVH and CAH. In eight cases of CAH combined with cirrhosis, NKMC (63.9±6.2) were significant lower than normal controls at E:T=50:1 (P<0.05). 4) In LC and HCC, NKMC were 37.3±13.1%, 37.2±13.8 (E:T=25:1) and 54.1±11.4%, 54.4±15.3% (E:T=50:1) respectively. They were significantly lower than in normal controls (P<0.01), And there were significant differencts compared to AVH 4 CAH (P<0.05). The NKMC of peripheral blood lymphocytes in asymptomatic HBV carrier and CAH were not significantly different each other. However, in LC and HCC there were significant differences compared to normal controls, 1t is suggested that NKMC was not relevant to the effector system af immunopathogenesis of liver cell injury in type B hepatitis virus infection Otherwise, depressed NKMC in LC might be one of the etiological factors in genesis of HCC in patient with LC.
이준욱(Joon Wook Lee),이성수(Seung Su Lee),박영민(Young Min Park),배시현(Si Hyun Bae),신제현(Je Hyun SHin),변병훈(Byung Hun Byun),최종영(Jong Young Choi),윤승규(Seung Kew Yoon),이영석(Young Sok Lee),이창돈(Chang Don Lee),차상복(Sang 대한소화기학회 2001 대한소화기학회지 Vol.38 No.4
Congenital non-parasitic splenic cysts comprise approximately 10% of all splenic cysts. Clinical manifestations in patients with splenic cyst are often nonspecific and ultrasound or CT is useful for its diagnosis. Total splenectomy has been the major way of treatment. However, currently, spleen-saving procedures are strongly recommended because of the immunological role of the spleen. One of such procedures, the percutaneous treatment with sclerosing agents has already been reported with a good result. In this report, we present a case of a 12×17 cm sized giant congenital splenic cyst treated with percutaneously using ethanol as a sclerosing agent. Seven-times of injections (total 140mL, 20mL/time, every 3 days) into the cystic cavity through the inserted catheter were performed for 3 weeks. After the treatment, the size of cyst decreased markedly in 8 months. On the basis of these results, we may conclude that the percutaneous ethanol ablation therapy is an alternative to surgical treatment for splenic cyst. (Korean J Gastroenterol 2001;38:300-303)
간세포암에서 담관 침범으로 다량 출혈을 일으킨 혈액담즙증
이경은 ( Kyung Eun Lee ),김창욱 ( Chang Wook Kim ),김민주 ( Min Ju Kim ),박진희 ( Jin Hee Park ),조규민 ( Gu Min Cho ),장정원 ( Jeong Won Jang ),이영석 ( Young Sok Lee ),이창돈 ( Chang Don Lee ) 대한소화기학회 2013 대한소화기학회지 Vol.61 No.1
Massive bleeding hemobilia occurs rarely in patients with hepatocellular carcinoma (HCC) without any invasive procedure. Upper gastrointestinal bleeding in patient with cirrhosis and abdominal pain with progressive jaundice in patient with HCC were usually thought as variceal bleeding and HCC progression respectively. We experienced recently massive bleeding hemobilia in patient with HCC who was a 73-year old man and showed sudden abdominal pain, jaundice and hematochezia. He had alcoholic cirrhosis and history of variceal bleeding. One year ago, he was diagnosed as HCC and treated with transarterial chemoembolization periodically. Sudden right upper abdominal pain occurred then subsided with onset of hemotochezia. Computed tomography showed bile duct thrombosis spreading in the intrahepatic and extrahepatic ducts, while an ampulla of vater bleeding was observed during duodenoscopy. Hemobilia could be one of the causes of massive bleeding in patients with cirrhosis and HCC especially when they had sudden abdominal pain and abrupt elevation of bilirubin. (Korean J Gastroenterol 2013;61:46-49)
간장 ( 肝臟 ) 및 담도 ( 膽道 ) : 간성뇌증에 대한 경구용 Branched - Chain Amino Acid ( AminolebanR EN ) 의 임상 효과
윤종만(Chong Man Yoon),최흥재(Heung Jai Choi),기춘석(Choon Suhk Kee),문한규(Han Kyu Moon),이창홍(Chang Hong Lee),김부성(Boo Sung Kim),이상인(Sang In Lee),장린(Rin Chang),이창돈(Chang Don Lee),류종선(Jong Sun Rew),곽규식(Kyu Sik Kwak 대한소화기학회 1991 대한소화기학회지 Vol.23 No.2
N/A The effects of oral branched-chain amino acids (Aminoleban EN) were investigated in 44 patients (male: 33, famale: 11, Mean age: 50.6 +- 8.4 years old) with decompensated liver cirrhosis and hepatic encephalopathy or history thereof in a multicenter collabo-ative clinical study. The following results were obtained. 1) Significant improvements were observed in indicators of neuropsychiatric symptoms such as asterixis, ability to make caIculations, number connection test times, encephalopathic grade and performance status among patients. 2) Plasma levels of branched-chain amino acids elevated significantly in the second week of treatment, and those of aromatic amino acids were in the decreasing trend after treatment, Fischers ratio were significanthy improved. 3) Serum levels of albumin in the patients with hypoalbuminemia (less than 3.0 gm%) were significantly elevated. 4) Adverse reactions reported in 3 cases (6.8%) out of 44 cases were abdominal pain, vomiting and abdominal distension with massive ascites. These results suggested that the supplementation of the diet with oral branched-chain amino acids may be beneficial effects in the patients with hepatic encephalopathy through the improvement of encephalopathy and nutritional status.